key: cord-0757613-tds9w7wq
authors: Dholaria, Bhagirathbhai; Malki, Monzr M. Al; Artz, Andrew; Savani, Bipin N.
title: Securing the graft during pandemic: are we ready for cryopreservation for all?
date: 2020-04-17
journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
DOI: 10.1016/j.bbmt.2020.04.009
sha: b3988dbeaf549eb69589724d6f309df346614f09
doc_id: 757613
cord_uid: tds9w7wq

nan

Allogeneic hematopoietic cell transplantation (allo-HCT) from an unrelated donor involves complex interplay of multiple organizations working together for a successful delivery of a stem cell graft to the recipient. Historically, cryopreservation of stem cell graft has been done only for a small fraction of allo-HCT due to concerns around negative impact of freezing and thawing on the viability of hematopoietic stem cells and function of donor lymphocytes (1) . Previous retrospective studies comparing allo-HCT outcomes of cryopreserved versus freshly infused peripheral blood stem cell (PBSC) graft from matched donors have shown comparable survival outcomes but marginally delayed neutrophil and platelet engraftment with cryopreservation (1, 2) . Some of these studies have shown increased risk of graft-versus-host disease (GvHD) at least with matched sibling donor but results were not consistent with matched unrelated donor grafts (2) (3) (4) . In absence of a prospective randomized study, the question of, 'Can a cryopreserved graft replace the freshly-infused graft in allo-HCT without compromising the outcomes?' The current study showed comparable survival outcomes between cryopreserved (n= 274) and

propensity-matched freshly infused grafts (n= 1080) in patients with various hematological malignancies and donor types. There was some suggestion of decreased risk for chronic GvHD and lower disease-free survival among the recipients of cryopreserved graft. The study did not detect any difference in overall survival however, sample size might be a limiting factor. Previous studies have shown reduced viability, proliferation and cytokine release capacity of donor lymphocytes after cryopreserved. Impaired alloreactivity of graft T cell due to cryopreservation may be a reason for reduced chronic GvHD incidence but higher risk for disease relapse. Natural Killer (NK) cells (CD56+) appear to have low tolerance to freezing and thawing process compared to other mononuclear cells (8) . This becomes important given delayed NK-cell reconstitution/maturation seen with PTCy (9). It could be another potential explanation for increased risk of disease relapse with cryopreserved graft, but this needs to be studied systemically. Type of cryopreservation media also appears to impact T cell viability which needs to further validated if cryopreservation becomes routine practice in the future (10) . The authors have correctly pointed out several limitations of the analysis, most importantly the lack of information about the reason for cryopreservation in individual patients. Additionally, immune reconstitution, surrogate markers of cell viability before and after cryopreservation and the influence of cryopreservation strategies require further study (10) .

COVID-19 has emerged as an existential threat to humanity and it is going to have lasting impact on our healthcare system. Travel restrictions, donor availability, blood product shortage and strained health care system secondary to COVID-19 pandemic have forced us to re-evaluate the current model of allo-HCT. In face of these challenges, both the National Marrow Donor Program (NMDP)(11) and the European Society for Blood and Marrow Transplantation (12) are strongly recommending cryopreservation of all unrelated donor grafts and some centers have moved to cryopreserve all related donor grafts. Thus, we welcome these data on cryopreserved grafts. There are several advantages of cryopreservation apart from logistical simplicity. Cryopreservation allows assurance that an adequate cell dose is available from an older or lower body mass related donor before conditioning regimen is started. It allows additional period of donor monitoring in case of exposure to a communicable disease such as COVID-19 before graft is infused. Cryopreservation may facilitate allocating a fraction of cells for storage for future donor lymphocyte infusion assuming pre-specified cell count thresholds are met (13) .

One should also note a few pitfalls of routine cryopreservation of stem cell graft. The largest uncertainty pertains to whether the delayed cryopreservation after significant travel will be detrimental for unrelated donor grafts. Couriers chaperoning unrelated grafts may face unpredictable delays due to transportation challenges during COVID-19 as grafts are chaperoned by a courier. This study included few unrelated grafts 56 (20%) which were not separately analyzed. Each day of delay of cryopreservation reduced viability by 5% for umbilical cords (14) . In one study showing significant engraftment failures, all failures occurred in patients receiving unrelated donor PBSC (9/25) as opposed to 0 of 8 receiving related PBSC grafts (15) . Apart from risks of infusion reaction from dimethyl sulfoxide, potential loss of cell dose from washing, routine cryopreservation is costly and may put further strain on stem cell processing facilities. Invariably, a few cryopreserved grafts will not be infused due to recipient related issues, which leaves the donor exposed to unnecessary health risks.

This registry-based analysis suggests relative safety of routine cryopreservation in the setting of PTCy. But a prospective registry study with appropriate follow up would best to establish safety and detect any pitfall or shortcoming of cryopreservation. The new recommendation of NMDP to cryopreservation of all unrelated donors due to COVID-19 crises will serve as a good stage for such a prospective study. We thank authors for doing this timely study as the results are rapidly applicable in the current era of COVID-19. It is important that our adaptations to post-COVID-19 world are rational and data-driven. The lessons learned from COVID-19 will only strengthen our ability to protect patients and donors from similar threats in the future.

Has allogeneic stem cell cryopreservation been given the 'cold shoulder'? An analysis of the pros and cons of using frozen versus fresh stem cell products in allogeneic stem cell transplantation

Cryopreservation of allogeneic PBSC from related and unrelated donors is associated with delayed platelet engraftment but has no impact on survival

Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts

To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors

Graft cryopreservation does not impact overall survival allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide for GVHD prophylaxis

Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

Phenotypical and functional analysis of donor lymphocyte infusion products after long-term cryopreservation

Immune reconstitution after T-cell replete HLA-haploidentical transplantation

Clinical methods of cryopreservation for donor lymphocyte infusions vary in their ability to preserve functional T-cell subpopulations

EBMT recommendation on: CORONAVIRUS DISEASE COVID-19: EBMT

Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor-Mobilized Donor Lymphocyte Infusions

Storage time affects umbilical cord blood viability

Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM